Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. (19th September 2018)

• Record Type: Journal Article
• Authors: Latagliata, Roberto; Breccia, Massimo; Carmosino, Ida; Cesini, Laura; De Benedittis, Daniela; Mohamed, Sara; Vozella, Federico; Molica, Matteo; Campanelli, Melissa; De Luca, Maria Lucia; Colafigli, Gioia; Quattrocchi, Luisa; Loglisci, Maria Giovanna; Massaro, Fulvio; Canichella, Martina; Diverio, Daniela; Mancini, Marco; Alimena, Giuliana; Foà, Robin
• Is Part Of: European journal of haematology. Volume 101:Number 5(2018)
• Page Start: 578
• Page End: 584
• Publication Date: 2018-09-19
• Subjects: chronic myeloid leukemia -- elderly -- imatinib -- prognosis; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13110
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objectives: To evaluate differences in clinical results according to age among patients with chronic myeloid leukemia (CML). Methods: 207 consecutive CML patients treated with imatinib frontline were revised, dividing them in young adults (>20 < 45 years) (YA), middle‐aged adults (≥45 < 65 years) (MA) and elderly (≥65 years) (EL). Results: Cumulative incidence of complete cytogenetic response (CCyR) and major molecular response (MMolR) were significantly higher in MA compared with YA and EL ( P < .001 for CCyR and P = .001 for MMolR). Number of total events was lower in MA (8 [11.1%] vs 21 [34.4%] in YA and 28 [37.8%] in EL, P = .001): no difference was observed for blastic evolution ( P = .478). Number of deaths was higher in the EL (12 [16.2%] vs 2 [3.2%] in YA and 0 in MA, P < .001): however, 11/12 deaths in EL were not related to CML. The PFS curve in MA was significantly longer than in YA and in EL ( P = .02). The OS curve in EL was significantly shorter than in YA and in MA ( P < .001). Conclusions: Age at diagnosis influences significantly the course of CML patients treated with imatinib: a possible explanation of the counterintuitive worse course in YA is the delayed diagnosis compared to elderly.